99Tc m-MIBI SPECT/CT tracking imaging of atypical parathyroid adenoma with recurrent fracture as the chief complaint: a case report
- Author:
- No author available
- Issue:
- 12
- DOI:
- 10.3760/cma.j.cn121381-202302012-00369
- Key Word:
- No keyword available
Abstract： This paper reports the imaging and clinical features of a patient with an atypical parathyroid adenoma characterized by recurrent fractures, high parathyroid hormone level, negative 99Tc m-methoxyisobutylisonitrile (MIBI) SPECT imaging at initial diagnosis and positive 99Tc m-MIBI SPECT/CT tracking imaging at follow-up. By reviewing and analyzing relevant literature, this paper aims to explore the diagnostic approach when both CT and ultrasound localization diagnostic results are negative, and even when the 99Tc m-MIBI SPECT/CT imaging are still negative, in order to improve the understanding and early diagnosis of atypical parathyroid adenoma and avoid clinical missed diagnosis.
- [1]Ma, Chao,Feng, Fang,Wang, Shaoyan,etc.Chinese Data of Efficacy of Low- and High-Dose Iodine-131 for the Ablation of Thyroid Remnant[J].2017,27(6).
- [2]Vardarli I.,Weidemann F.,Aboukoura M.,etc.Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis[J].2020,20(1).
- [3]Schlumberger,M.,Catargi,B.,Borget,I.,etc.Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J].2012,366(18).
- [4]Takavar,A.,Gilani,K.A.,Eftekhari,M.,etc.Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: A large randomized clinical trial[J].2012,33(3).
- [5]A R, Jadad,R A, Moore,D, Carroll,etc.Assessing the quality of reports of randomized clinical trials: is blinding necessary?[J].1996,17(1).
- [6]Haugen, Bryan R.,Alexander, Erik K.,Bible, Keith C.,etc.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].2016,26(1).
- [7]Veera Ahtiainen,Leila Vaalavirta,Mikko Tenhunen,etc.Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up[J].2020,59(9).
- [8]Song, Xinghua,Meng, Zhaowei,Jia, Qiang,etc.Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer A Meta-analysis[J].2015,40(10).
- [9]Kukulska Aleksandra,Krajewska Jolanta,Gawkowska-Suwińska Marzena,etc.Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi[J].2010,3(1).
- [10].Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study.[J].2008.
- [11]Schlumberger, Martin,Leboulleux, Sophie,Catargi, Bogdan,etc.Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial[J].2018,6(8).
- [12]Yap,B.,Nutting,C.M.,Kadalayil,L.,etc.Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer[J].2012,366(18).
- [13]Dehbi, Hakim-Moulay,Mallick, Ujjal,Wadsley, Jonathan,etc.Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial[J].2019,7(1).
- [14]中华医学会核医学分会.131I治疗格雷夫斯甲亢指南（2021版）[J].2021,(4).